Madina Adil
Madina Adil is a Senior Manager of Health and Reimbursement Policy at Kimbell & Associates. In her role, Ms. Adil advocates for client priorities through the rulemaking process and represents biopharmaceutical companies seeking new codes such as ICD-10 and HCPCS. Ms. Adil also serves as Manager of Health Policy and Advocacy for the Institute for Gene Therapies (IGT), a non-profit advocacy organization launched in 2020 to help address coverage, access, and reimbursement challenges surrounding gene therapies.
Prior to joining the firm in 2020, Ms. Adil served as a Fellow in the Policy and Research department at the Pharmaceutical Research & Manufacturers of America (PhRMA). During her time at PhRMA, she focused on issues related to biopharmaceutical value assessment, innovative contracting, and the COVID-19 vaccine and treatment development pipeline.
Previously, Ms. Adil served as a Research Associate in the Department of Health Policy and Management at the George Washington University (GWU). Her research centered on legal and policy aspects of the evolving health care system, examining how they impact various public health programs and prevention issues. Before this, she held positions at the National Partnership for Women & Families and March of Dimes, working on key issues ranging from health information technology to maternal and child health outcomes. Ms. Adil has also held clinical roles at Inova Children’s Hospital, where she focused on pediatric oncology care, and the Arlington Free Clinic, where she worked with medically underserved populations.
Ms. Adil graduated magna cum laude from George Mason University with a BS in biology and received her MPH with a concentration in health policy and management from the GWU School of Public Health. She also holds an MS in microbiology and emerging infectious diseases from GWU.
Prior to joining the firm in 2020, Ms. Adil served as a Fellow in the Policy and Research department at the Pharmaceutical Research & Manufacturers of America (PhRMA). During her time at PhRMA, she focused on issues related to biopharmaceutical value assessment, innovative contracting, and the COVID-19 vaccine and treatment development pipeline.
Previously, Ms. Adil served as a Research Associate in the Department of Health Policy and Management at the George Washington University (GWU). Her research centered on legal and policy aspects of the evolving health care system, examining how they impact various public health programs and prevention issues. Before this, she held positions at the National Partnership for Women & Families and March of Dimes, working on key issues ranging from health information technology to maternal and child health outcomes. Ms. Adil has also held clinical roles at Inova Children’s Hospital, where she focused on pediatric oncology care, and the Arlington Free Clinic, where she worked with medically underserved populations.
Ms. Adil graduated magna cum laude from George Mason University with a BS in biology and received her MPH with a concentration in health policy and management from the GWU School of Public Health. She also holds an MS in microbiology and emerging infectious diseases from GWU.
